ATOMOXETINE TREATMENT FOR PEDIATRIC PATIENTS WITH ADHD AND COMORBID ANXIETY

Abstract

Objectives: Research indicates 25%-50% comorbidity of anxiety disorders with attention-deficit/hyperactivity disorder (ADHD). Atomoxetine is a nonstimulant approved for treating ADHD that is not contraindicated in the presence of anxiety disorders. This study compared atomoxetine with placebo in treating pediatric patients with ADHD and comorbid anxiety, as measured by the ADHDRS-IV-Parent: Inv (ADHDRS) Total Score and the Pediatric Anxiety Rating Scale (PARS) Total Score.